The search for molecular precursors of cancer in the fallopian tubes is largely driven by emerging evidence supporting it as the site of origin for many ovarian cancers.
This study evaluated the rates of germline and somatic BRCA testing in women with ovarian cancer included in the Flatiron Health database.
PAOLA-1/ENGOT-ov25 is a phase 3 clinical trial evaluating a first-line olaparib plus bevacizumab maintenance regimen in patients with advanced ovarian cancer.
This analysis presents preliminary data for secondary endpoints of TFST and PFS2 from the phase 3 PRIMA/ENGOTOV26/GOG-3012 study.
JAVELIN Ovarian 100 was the first phase 3 study to evaluate an immune checkpoint inhibitor in previously untreated advanced epithelial ovarian cancer.
Regardless of birthplace, women who are Asian Pacific Islanders appear to have a higher risk of developing ovarian clear cell cancer compared with other ethnicities.
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
CMS recently announced that patients with germline ovarian or breast cancer would be covered for diagnostic testing that uses next-generation sequencing.
A pervading theme of this guideline was the importance of including genetic counselors in the interpretation and communication of germline and somatic testing results.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
